新药审批正大天晴 TQB3142 TQB31228月12日,正大天晴宣布,其2款1类新药的临床试验申请(IND)获国家药品监督管理局(NMPA)受理,分别为Bcl-xL PROTAC药物TQB3142、高选择性PARP1抑制剂TQB3122。2款新药拟用于治疗恶性肿瘤,目前全球范围内均未有同类产品上市。恒瑞医药 海曲泊帕乙醇胺片8月12日,恒瑞医药宣布其自主研发的1类新药海曲泊帕乙醇胺片的药品上市...
Source Link新药审批正大天晴 TQB3142 TQB31228月12日,正大天晴宣布,其2款1类新药的临床试验申请(IND)获国家药品监督管理局(NMPA)受理,分别为Bcl-xL PROTAC药物TQB3142、高选择性PARP1抑制剂TQB3122。2款新药拟用于治疗恶性肿瘤,目前全球范围内均未有同类产品上市。恒瑞医药 海曲泊帕乙醇胺片8月12日,恒瑞医药宣布其自主研发的1类新药海曲泊帕乙醇胺片的药品上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.